Natalizumab antibody | AbD21375_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human anti natalizumab, clone AbD21375_hIgG1 (HCA249P) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) followed by QuantaBlu™ fluorogenic peroxidase substrate.
A microtiter plate was coated over night with natalizumab, human IgG4/kappa or human IgG1/kappa at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human anti natalizumab, clone AbD21375_hIgG1 (HCA249P) titrated to the given concentrations in PBST, followed by QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements
A microtiter plate was coated over night with Human anti natalizumab, clone AbD21375 (HCA248) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of natalizumab. Detection was performed using HRP-conjugated Human anti natalizumab, clone AbD21375_hIgG1 (HCA249P) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements.
A microtitre plate was coated over night with natalizumab at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human anti natalizumab, clone AbD21375_hIgG1 (HCA249) or clone AbD21384_hIgG1 (HCA250). Detection was performed using HRP-conjugated natalizumab. HRP-conjugation of natalizumab used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®. Data is presented as the mean of three measurements
Human anti Natalizumab:HRP
Anti-natalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for natalizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
Human anti Natalizumab
Anti-natalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for natalizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
- Product Type
- Monoclonal Antibody
- Clone
- AbD21375_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| HCA249P | E | 0.1 mg |
|
|
| HCA249 | E | 0.1 mg |
|
Human Anti-Natalizumab Antibody, clone AbD21375_hIgG1 is a paratope specific, anti-idiotypic antibody that specifically recognizes free natalizumab but not free human alpha-4/beta-1 integrin or the drug/integrin complex. It inhibits the binding of natalizumab to its target and can be used to measure levels of free natalizumab and biosimilar products in bioanalytical and patient monitoring assays.
Clone AbD21375_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay. Additionally it can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody, paired with Anti-Natalizumab Antibody clone AbD21375 (HCA248) in monovalent Fab format as the capture antibody.
Natalizumab (Tysabri) is a humanized IgG4/kappa monoclonal antibody approved as a monotherapy for the treatment of relapsing forms of multiple sclerosis and for the treatment of Crohn’s disease. It is directed against alpha-4 integrin (CD49d), and binds to alpha-4/beta-1 integrin on the surface of circulating leucocytes, except neutrophils. It is believed to act by blocking the interaction of alpha-4/beta-1 integrin with vascular cell adhesion molecule-1 (VCAM-1), preventing the adherence and transport of inflammatory immune cells across the intestinal lining and blood-brain barrier.
View a summary of all anti-natalizumab antibodies
Clone AbD21375_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay. Additionally it can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody, paired with Anti-Natalizumab Antibody clone AbD21375 (HCA248) in monovalent Fab format as the capture antibody.
Natalizumab (Tysabri) is a humanized IgG4/kappa monoclonal antibody approved as a monotherapy for the treatment of relapsing forms of multiple sclerosis and for the treatment of Crohn’s disease. It is directed against alpha-4 integrin (CD49d), and binds to alpha-4/beta-1 integrin on the surface of circulating leucocytes, except neutrophils. It is believed to act by blocking the interaction of alpha-4/beta-1 integrin with vascular cell adhesion molecule-1 (VCAM-1), preventing the adherence and transport of inflammatory immune cells across the intestinal lining and blood-brain barrier.
View a summary of all anti-natalizumab antibodies
Product Details
- Product Form
- Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Natalizumab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD = 2.1 nM by real time, label free molecular interaction analysis on immobilized natalizumab.
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Tysabri® is a registered trademark Biogen Idec and Elan.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Tysabri® is a registered trademark Biogen Idec and Elan.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Natalizumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA248 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug - ELISA
- This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA248 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
This antibody is fully human and can be used as a reference standard in an ADA assay.
Protocol: ADA bridging ELISA
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Natalizumab | HCA248 | E | 0.1 mg |
|
|
| Human anti Natalizumab | HCA250 | E | 0.1 mg |
|
|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Natalizumab | HCA248 | E | 0.1 mg |
|
|
| Human anti Natalizumab | HCA250 | E | 0.1 mg |
|
|
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | ||
| Mouse anti Human IgG (Fc) CH2 Domain:HRP | MCA647P | C* E | 0.2 mg |
|
Product Specific References
References for Natalizumab antibody
-
Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
US Patent US20170315118A1
